Friday Satellite Symposia
Lymphomas, Clinical Practice (Health Services and Quality), Education, Diseases, Treatment Considerations, Lymphoid Malignancies
Marriott Grand Ballroom 2-4
(Marriott Marquis San Diego Marina)
Chair:
Wendy Osborne, MD, Consultant Haematologist, Honorary Clinical Senior Lecturer, Newcastle Hospitals – Newcastle University
Disclosures:
Osborne: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria; Kite Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria; Novartis: Honoraria; Kyowa Kirin: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Autolus: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees; Syneos: Membership on an entity's Board of Directors or advisory committees.
Speakers:
Gareth P. Gregory, MBBS(Hons), PhD, Associate Professor, Monash Health and Monash University
,
Natacha Bolaños, ARRAY(0xe630a84)
and
Gilles Salles, MD, PhD, Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center
Disclosures:
Gregory: Merck, BeiGene (to institute, not individual): Research Funding; Roche, Merck: Speakers Bureau; Merck, Amgen, Roche, Novartis, BMS, Clinigen, Gilead, Prelude Therapeutics: Membership on an entity's Board of Directors or advisory committees. Salles: AbbVie: Consultancy, Research Funding; BeiGene: Consultancy; BMS/Celgene: Consultancy; Genentech/Roche: Consultancy, Honoraria, Research Funding; Genmab: Consultancy, Research Funding; Incyte: Consultancy, Honoraria; Ipsen: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Kite/Gilead: Consultancy; Merck: Consultancy; Molecular Partners: Consultancy; Nurix: Research Funding; Debiopharm: Consultancy; Epizyme: Consultancy; Innate Pharma: Consultancy; Orna Therapeutics: Consultancy; Pfizer: Consultancy; Treeline: Consultancy; Owkin: Divested equity in a private or publicly-traded company in the past 24 months.
On Demand program will be available here December 21, 2024.
Access Program Here
The options for treatment of diffuse large B-cell lymphoma (DLBCL) have expanded in recent years, particularly with the emergence of bispecific antibodies. Today's activity will focus on enhancing knowledge and competence in managing DLBCL at first relapse. The agenda includes discussions on treatment goals, factors influencing eligibility for different therapies, patient experiences, personalized treatment selection, and the emerging role of bispecific antibodies. You will learn about the patient perspective, communication strategies for shared decision-making, and considerations for integrating new therapies like bispecific antibodies. Interactive case-based discussions will highlight physician and patient perspectives in selecting therapy for patients who are not candidates for transplant or chimeric antigen receptor (CAR) T-cell therapy. The session will end with essential insights from the expert faculty, summarizing today's DLBCL management journey.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.